Zacks Investment Research on MSN
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why
Humacyte, Inc. (HUMA) closed at $0.68 in the latest trading session, marking a -7.13% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.26%. On the other hand, ...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Humacyte, Inc.
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed ...
Zacks Investment Research on MSN
Humacyte, Inc. (HUMA) stock declines while market improves: Some information for investors
Humacyte, Inc. (HUMA) closed at $0.61 in the latest trading session, marking a -6.63% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.08%. Meanwhile, the Dow ...
DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial ...
(RTTNews) - Humacyte, Inc. (HUMA) has launched Symvess, a bioengineered vascular conduit for adults needing urgent revascularization due to extremity arterial injury when autologous vein grafts aren't ...
- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase commitment received for a minimum of $1.475 million for a ...
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company ...
DURHAM, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial ...
In the latest trading session, Humacyte, Inc. (HUMA) closed at $2.09, marking a -1.42% move from the previous day. This change lagged the S&P 500's daily gain of 0.52%. Meanwhile, the Dow gained 0.63% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results